While the role of chemokines in cancer has been extensively studied, only three chemokine-targeting drugs have received FDA approval to date: maraviroc, which targets CCR5; plerixafor, which targets CXCR4; and mogamulizumab, which targets CCR4 [205,206,207]. This evidence concerns the gene CXCR4 and cancer.